Effects of Cyclosporin A on Lung Cancer Cells
Author Information
Author(s): P.R. Twentyman, K.A. Wright, H.M. Wallace
Primary Institution: MRC Clinical Oncology and Radiotherapeutics Unit, University of Cambridge; Department of Medicine and Therapeutics and Biomedical Sciences (Pharmacology), University of Aberdeen
Hypothesis
Can cyclosporin A and its analogue inhibit the growth of human lung cancer cells in vitro?
Conclusion
Cyclosporin A and its analogue can inhibit the growth of human lung cancer cells in vitro, but only at doses that are not clinically achievable.
Supporting Evidence
- Cyclosporin A produced partial growth inhibition at doses ranging from 0.5 to 3.0 µg/ml.
- At progressively higher doses, complete growth inhibition and in situ cell lysis were observed.
- The P-glycoprotein expressing multidrug resistant variant was less sensitive to cyclosporins than the parent line.
- Sensitivity to the analogue O-acetyl cyclosporin A was approximately 2-fold higher than that to cyclosporin A in most lines.
Takeaway
This study looked at how a drug called cyclosporin A affects lung cancer cells in a lab. It found that the drug can stop the cancer cells from growing, but only at very high doses that doctors can't use safely.
Methodology
The study used continuous drug exposure and the MTT colorimetric assay to determine cell growth inhibition in various human lung cancer cell lines.
Limitations
The doses required for growth inhibition are higher than those that can be achieved clinically.
Want to read the original?
Access the complete publication on the publisher's website